Navidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (“Navidea” or “the Company”), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 7th Annual LD Micro Invitational investor conference being held June 6-7, 2017 in Los Angeles, CA. Michael Goldberg, M.D., Chief Executive Officer of Navidea, will be giving a presentation and meeting with investors throughout the conference.
Event: 7th Annual LD Micro Invitational
Presentation Date: June 6, 2017
Presentation Time: 3:00 PM PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Dr. Goldberg said, “I am proud to give an introduction to, and in some cases an update of, Navidea to high-quality investors. We’ve recently achieved significant milestones and have a pipeline of clinical development announcements upcoming. Navidea is at an exciting point, and we are eager to share our plans with the investment community.”
“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history,” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”
The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the Events tab of the Investor Relations section of the Navidea website at www.navidea.com.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its ManoceptTM platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.
Source: Navidea Biopharmaceuticals, Inc.
Released June 1, 2017